Clinical research progress of human respiratory syncytial virus vaccine.
10.3760/cma.j.cn112150-20220822-00831
- Author:
Ming Yue JIANG
1
;
Yun Shao XU
1
;
Song Tao XU
2
;
Lu Zhao FENG
1
Author Information
1. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
2. National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
- Publication Type:Journal Article
- MeSH:
Infant;
Humans;
Aged;
Respiratory Syncytial Virus, Human;
Respiratory Syncytial Virus Infections/epidemiology*;
Respiratory Syncytial Virus Vaccines/therapeutic use*;
Respiratory Tract Infections
- From:
Chinese Journal of Preventive Medicine
2023;57(1):70-77
- CountryChina
- Language:Chinese
-
Abstract:
Human respiratory syncytial virus (HRSV) is one of the main pathogen causing severe acute lower respiratory tract infections in infants and the elderly, with high incidence rate and mortality worldwide. Vaccine is one of the important measure to prevent infection, transmission and severe disease of HRSV, but currently there is no officially approved preventive vaccine for prevention of HRSV in the world. This paper reviews and analyzes the current research and development progress of HRSV vaccine, summarizes the design routes of different types of HRSV preventive vaccines, and discusses the difficulties and challenges in vaccine research and development, in order to provide reference for the research and development of HRSV vaccine and the development of clinical trials.
